Literature DB >> 27563707

Aptamer and its applications in neurodegenerative diseases.

Jing Qu1, Shuqing Yu2, Yuan Zheng1, Yan Zheng1, Hui Yang1, Jianliang Zhang3.   

Abstract

Aptamers are small single-stranded DNA or RNA oligonucleotide fragments or small peptides, which can bind to targets by high affinity and specificity. Because aptamers are specific, non-immunogenic and non-toxic, they are ideal materials for clinical applications. Neurodegenerative disorders are ravaging the lives of patients. Even though the mechanism of these diseases is still elusive, they are mainly characterized by the accumulation of misfolded proteins in the central nervous system. So it is essential to develop potential measures to slow down or prevent the onset of these diseases. With the advancements of the technologies, aptamers have opened up new areas in this research field. Aptamers could bind with these related target proteins to interrupt their accumulation, subsequently blocking or preventing the process of neurodegenerative diseases. This review presents recent advances in the aptamer generation and its merits and limitations, with emphasis on its applications in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, transmissible spongiform encephalopathy, Huntington's disease and multiple sclerosis.

Entities:  

Keywords:  Alzheimer’s disease; Aptamer; Huntington’s disease; Multiple sclerosis; Neurodegenerative diseases; Parkinson’s disease; Transmissible spongiform encephalopathy

Mesh:

Substances:

Year:  2016        PMID: 27563707     DOI: 10.1007/s00018-016-2345-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  132 in total

1.  Bringing picomolar protein detection into proximity.

Authors:  Michael Famulok
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

Review 2.  LNA: a versatile tool for therapeutics and genomics.

Authors:  Michael Petersen; Jesper Wengel
Journal:  Trends Biotechnol       Date:  2003-02       Impact factor: 19.536

3.  In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection.

Authors:  J G Bruno; J L Kiel
Journal:  Biosens Bioelectron       Date:  1999-05-31       Impact factor: 10.618

4.  Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo.

Authors:  S R Watson; Y F Chang; D O'Connell; L Weigand; S Ringquist; D H Parma
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2000-04

5.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

Review 6.  Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms.

Authors:  Maria C Rodriguez-Oroz; Marjan Jahanshahi; Paul Krack; Irene Litvan; Raúl Macias; Erwan Bezard; José A Obeso
Journal:  Lancet Neurol       Date:  2009-12       Impact factor: 44.182

Review 7.  Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment.

Authors:  Sasanka Chakrabarti; Vineet Kumar Khemka; Anindita Banerjee; Gargi Chatterjee; Anirban Ganguly; Atanu Biswas
Journal:  Aging Dis       Date:  2015-08-01       Impact factor: 6.745

8.  Inhibiting α-synuclein oligomerization by stable cell-penetrating β-synuclein fragments recovers phenotype of Parkinson's disease model flies.

Authors:  Ronit Shaltiel-Karyo; Moran Frenkel-Pinter; Nirit Egoz-Matia; Anat Frydman-Marom; Deborah E Shalev; Daniel Segal; Ehud Gazit
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

9.  Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.

Authors:  Huiyu Liang; Yusheng Shi; Zhewen Kou; Yonghua Peng; Wenjun Chen; Xiaowen Li; Shuji Li; Ying Wang; Fang Wang; Xingmei Zhang
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

10.  Characterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion.

Authors:  Alexandre Rhie; Louise Kirby; Natalie Sayer; Rosanna Wellesley; Petra Disterer; Ian Sylvester; Andrew Gill; James Hope; William James; Abdessamad Tahiri-Alaoui
Journal:  J Biol Chem       Date:  2003-08-05       Impact factor: 5.157

View more
  16 in total

1.  Selection and Application of Aptamer Affinity for Protein Purification.

Authors:  Ana Paula de Jesus Santos; Ágatha Oliveira-Giacomelli; Vanessa Karen de Sá; Isis Cristina do Nascimento; Erika de Simone Molina; Henning Ulrich
Journal:  Methods Mol Biol       Date:  2022

2.  Recent Advances in Supramolecular Affinity Separations: Affinity Chromatography and Related Methods.

Authors:  Ashley G Woolfork; Sazia Iftekhar; Susan Ovbude; Kyungah Suh; Sadia Sharmeen; Isaac Kyei; Jacob Jones; David S Hage
Journal:  Adv Chromatogr       Date:  2021       Impact factor: 0.400

3.  Fighting the Huntington's Disease with a G-Quadruplex-Forming Aptamer Specifically Binding to Mutant Huntingtin Protein: Biophysical Characterization, In Vitro and In Vivo Studies.

Authors:  Claudia Riccardi; Federica D'Aria; Filomena Anna Digilio; Maria Rosaria Carillo; Jussara Amato; Dominga Fasano; Laura De Rosa; Simona Paladino; Mariarosa Anna Beatrice Melone; Daniela Montesarchio; Concetta Giancola
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

Review 4.  Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders.

Authors:  Islauddin Khan; Kumari Preeti; Valencia Fernandes; Dharmendra Kumar Khatri; Shashi Bala Singh
Journal:  Cell Mol Neurobiol       Date:  2021-05-01       Impact factor: 4.231

Review 5.  Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery.

Authors:  Pascal Röthlisberger; Cécile Gasse; Marcel Hollenstein
Journal:  Int J Mol Sci       Date:  2017-11-16       Impact factor: 5.923

Review 6.  Aptamers Selected for Recognizing Amyloid β-Protein-A Case for Cautious Optimism.

Authors:  Farid Rahimi
Journal:  Int J Mol Sci       Date:  2018-02-27       Impact factor: 5.923

Review 7.  Amyloid-beta immunotherapy: the hope for Alzheimer disease?

Authors:  Alvaro Barrera-Ocampo; Francisco Lopera
Journal:  Colomb Med (Cali)       Date:  2016-12-30

8.  Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation.

Authors:  Yuan Zheng; Jing Qu; Fenqin Xue; Yan Zheng; Bo Yang; Yongchang Chang; Hui Yang; Jianliang Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2018-03-06       Impact factor: 8.886

Review 9.  Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics.

Authors:  Domenica Musumeci; Chiara Platella; Claudia Riccardi; Federica Moccia; Daniela Montesarchio
Journal:  Cancers (Basel)       Date:  2017-12-20       Impact factor: 6.639

Review 10.  Unraveling Prion Protein Interactions with Aptamers and Other PrP-Binding Nucleic Acids.

Authors:  Bruno Macedo; Yraima Cordeiro
Journal:  Int J Mol Sci       Date:  2017-05-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.